In non-small cell lung cancer (NSCLC), several ICI are also approved for metastatic disease, such as pembrolizumab, nivolumab, and cemiplimab (anti-PD1 mAb) and atezolizumab and durvalumab (anti-PDL1 mAb), either as monotherapy or in combination with chemotherapy, depending on PDL1 expression and treatment setting [53–55]. Here, PDCD1 is linked to non-small cell lung carcinoma.